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Introduction {#sec001}
============

Angiotensin-converting enzyme inhibitors (ACEis) are used to treat cardiovascular diseases and diabetic nephropathy \[[@pone.0224858.ref001]\]. A 3-year follow-up of cardiovascular disease patients found that ACEi treatment reduced mortality by 18% compared to a placebo-treated group \[[@pone.0224858.ref002]\]. ACEis inhibit the conversion of angiotensin I to angiotensin II by angiotensin-converting enzyme (ACE). Angiotensin II is a vasoconstrictor which increases blood pressure \[[@pone.0224858.ref003]\]. ACEis are prescribed to approximately 40 million people worldwide. Up to 0.7% of ACEi users develop angioedema which is a well-known adverse drug reaction (ADR) \[[@pone.0224858.ref004]\]. Angioedema is a non-itchy swelling of the deeper layers of the skin or mucosa and may occur in various parts of the body. This symptom may be fatal when it leads to airway obstruction \[[@pone.0224858.ref005]\]. Upper airway swellings have occured in as many as fifty percent of ACEi-induced angioedema (ACEi-AE) cases \[[@pone.0224858.ref006]\]. Angioedema can develop within a few minutes, blocking the respiratory tract. This requires emergency treatment including intubation or in very severe cases, acute tracheotomy\[[@pone.0224858.ref007]\].

The pathophysiology of ACEi-AE has been linked to bradykinin (BK) and potentially substance P \[[@pone.0224858.ref008],[@pone.0224858.ref009]\]. BK is a potent vasodilator which enhances the permeability of capillaries leading to fluid leakage into the surrounding tissues \[[@pone.0224858.ref010]\]. In healthy individuals, BK is degraded by ACE, aminopeptidase P (APP), neutral endopeptidase, dipeptidylpeptidase IV and carboxypeptidase N \[[@pone.0224858.ref011]--[@pone.0224858.ref013]\]. A small amount of BK is converted into the active metabolite, des-arginine-9-bradykinin, by the enzyme carboxypeptidase N. This metabolite is also degraded by ACE and APP \[[@pone.0224858.ref012]\].

The risk of developing ACEi-AE may be affected by a patient's ethnicity or sex, and also by smoking, seasonal allergies or immunosuppressant treatment \[[@pone.0224858.ref014]\]. Patients who are black and/or female have an increased risk of developing ACEi-AE, whereas diabetes seems to be protective \[[@pone.0224858.ref014],[@pone.0224858.ref015]\]. Several studies have investigated associations between genetic variations and ACEi-AE but the results have been inconsistent \[[@pone.0224858.ref016]--[@pone.0224858.ref022]\]. This study systematically reviews the current literature on genetic susceptibility to ACEi-AE and evaluates the methodology of included studies using the newly developed "quality of genetic associations studies tool" (Q-genie) \[[@pone.0224858.ref023]\].

Materials and methods {#sec002}
=====================

Protocol and search strategy {#sec003}
----------------------------

The search period was set up until August 2018. A complementary literature search was performed in September 2019 and no further relevant papers were published since the time of our original search. The Cochrane Database of Systematic Reviews, Google Scholar, and PubMed were searched to retrieve the relevant papers based on the predefined search terms and strategy. To maximize the search coverage, a combination of medical subject heading (MeSH) terms for "angiotensin converting enzyme inhibitors", "angioedema", "genetic markers", "polymorphisms", and "pharmacogenetics" were included. Furthermore the bibliographies of retrieved papers were assessed to identify further studies.

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed for this systematic review and our protocol was registered and published with the Prospective Register of Systematic Reviews (PROSPERO) ref. CRD42016041639 \[[@pone.0224858.ref024],[@pone.0224858.ref025]\].

Eligibility criteria {#sec004}
--------------------

Studies were eligible if they included patients who developed angioedema during treatment with ACEis. Observational case-control studies, clinical trials, cohort studies, case reports, case series, and other observational or experimental studies were all considered eligible. Reviews, studies not written in English, animal studies, conference abstracts (if the full study was not published) and studies of angioedema induced by other conditions or medication were all excluded \[[@pone.0224858.ref025]\].

Selection of studies and data extraction {#sec005}
----------------------------------------

After removing duplicates, the study titles and abstracts were screened independently by two reviewers (ERR, TH) to exclude those that did not meet the inclusion criteria. The full-text of each remaining study was evaluated. Disagreements between the reviewers were resolved by discussion. Studies were included if they investigated the relationship between genetic polymorphisms and ACEi-AE. The following information was extracted for each included study: first author's name, publication year, study design and main findings of the studies. Two independent reviewers checked the information for precision (ERR, TH) \[[@pone.0224858.ref025]\].

Quality assessment {#sec006}
------------------

Four reviewers (HAA, ERR, AFL, SHM) independently assessed the quality of each included study using Q-genie tool. This tool is specifically designed to facilitate quality assessment of genetic studies and to evaluate the risk of bias \[[@pone.0224858.ref023]\]. The Q-genie tool consists of 11 questions which address the following aspects of study methodologies: study rationale, outcome, comparability, exposure, bias, sample size, analyses, statistical methods and control for confounding, inferences for genetic analyses and inferences drawn from results.

Each question was scored from 1--7 as follows: \"1 (poor)\", \"2\", \"3 (good)\", \"4\", \"5 (very good)\", \"6\" or \"7 (excellent)\". For studies with control groups, a total score of ≤35 indicates poor quality, a score of 36--45 indicates moderate quality and a score of \>45 indicates good quality. In studies without control groups, a total score of ≤32 indicates poor quality, a score between 33--40 indicates moderate quality and a score of \> 40 indicates good quality \[[@pone.0224858.ref023]\].

Ethics {#sec007}
------

This study did not require any approval from the ethics committee.

Results {#sec008}
=======

Study selection {#sec009}
---------------

The strategy described in materials and methods was used to search electronic bibliographic databases (Cochrane Database of Systematic Reviews, Google Scholar, and PubMed) and 404 studies were identified. Next, 261 duplicates were removed, and the remaining 143 studies were screened for content. Of these studies, 119 did not meet the inclusion criteria. The full-text of each of the remaining 24 studies was assessed, and 17 studies were excluded. The detailed study selection procedure is shown in [Fig 1](#pone.0224858.g001){ref-type="fig"}. Seven studies met all the inclusion criteria.

![PRISMA flow diagram showing study selection procedure.](pone.0224858.g001){#pone.0224858.g001}

Quality assessment {#sec010}
------------------

The seven included studies were scored using the Q-Genie tool \[[@pone.0224858.ref016]--[@pone.0224858.ref022]\]. [Table 1](#pone.0224858.t001){ref-type="table"} provides an overview of the included studies, their characteristics and the total scores for each of the selected studies, using the Q-genie tool. [S1 Table](#pone.0224858.s001){ref-type="supplementary-material"} provides detailed information on the scores of each study. One study by Paré et al. was of \"good quality\" and the remaining six studies were graded of \"moderate quality\".

10.1371/journal.pone.0224858.t001

###### Outcomes reported by studies investigating the relationship between ACEi-induced angioedema and gene polymorphisms.

![](pone.0224858.t001){#pone.0224858.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author and year of publication                Study design         Country                Ethnicity                                  Age means ± SD (years)   Gender (F, %)   Participants (treatment duration with ACEi)   Genotyping                    Polymorphisms                          Main findings                                                                                                                                                                                                                                                                       The total score based on the Q-genie tool
  --------------------------------------------------- -------------------- ---------------------- ------------------------------------------ ------------------------ --------------- --------------------------------------------- ----------------------------- -------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------
  **Bas 2009** \[[@pone.0224858.ref016]\]             Case-control study   Germany                NS                                         62 ±\                    47              65 cases *(36*,*7 ±*\                         Allele-specific PCR           *ACE* I/D (rs 4646994)\                No significant association was found between *ACE* I/D or *BDKRB2* 2/3 and c.C181T *(BDKRB2* c.40\> T rs1046248*)* gene polymorphism and ACEi-AE                                                                                                                                    42
                                                                                                                                             1,6                                      *4*,*8 months)*\                                                            *BDKRB2* 2/3\                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                      65 controls\                                                                *BDKRB2* c.C181T\                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                      *(49 ±*\                                                                    (*BDKRB2* c.40\> T rs1046248)                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                      *3*,*5 months)*                                                                                                                                                                                                                                                                                                                                                                                        

  **Duan 2005** \[[@pone.0224858.ref022]\]            Case-control study   USA, Canada, Belgium   Caucasian                                  NS                       NS              20 cases *(less than 8 years)*\               Allele-specific PCR           *XPNPEP2* C-2399A\                     *XPNPEP2* C-2399A (*XPNPEP2* c.-2400C\>A rs3788853) is correlated with decreased APP activity and thus a greater incidence of ACEi-AE                                                                                                                                               39
                                                                                                                                                                                      60 controls                                                                 (*XPNPEP2* c.-2400C\>A rs3788853)                                                                                                                                                                                                                                                                                          

  **Gulec 2008** \[[@pone.0224858.ref017]\]           Case-control study   Turkey                 Caucasian                                  58,06 ± 8,71             72,4            32 cases\                                     PCR                           *ACE* I/D                              No association was found between *ACE* gene polymorphism and ACEi-AE or ATRB-AE                                                                                                                                                                                                     36
                                                                                                                                                                                      *(less than 36 months)*\                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                      46 controls\                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                      *(NS)*                                                                                                                                                                                                                                                                                                                                                                                                 

  **La Corte 2011** \[[@pone.0224858.ref020]\]        Case-control study   USA, Canada, Belgium   NS                                         NS                       NS              34 cases *(NS)*\                              TaqMan SNP genotyping         *XPNPEP2* C-2399A\                     A functional ATG haplotype was found in the 5'regulatory region of *XPNPEP2*; this region is correlated with an increased risk of ACEi-AE due to decreased APP activity. The ATG haplotype is more informative than the\                                                            37
                                                                                                                                                                                      127 controls *(NS)*                                                         (*XPNPEP2* c. C.-2400C\>A rs3788853)   *XPNPEP2* C-2399A polymorphism (*XPNPEP2* c. C.-2400C\>A rs3788853)                                                                                                                                                                                                                 

  **Moholisa 2013**\[[@pone.0224858.ref021]\]         Case-control study   South Africa           Black, Caucasian and Cape mixed ancestry   49                       79              52 cases *(NS)*\                              Allel-specific PCR and RFLP   *ACE* I/D\                             The association between Bradykinin receptor B2--9 /+ 9 and the development of ACEi-AE and ACE-cough was significant.\                                                                                                                                                               40
                                                                                                                                                                                      77 controls *(2 years)*                                                     *BDKRB2*--9/+9\                        No significant correlation shown between *ACE* I/D or *BDKRB2* C-58T (*BDKRB2* c.-192T\>C rs1799722) polymorphism and ACEi-AE and ACE-cough                                                                                                                                         
                                                                                                                                                                                                                                                                  *BDKRB2* C-58T\                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                  (*BDKRB2* c.-192T\>C rs1799722)                                                                                                                                                                                                                                                                                            

  **Pare**\[[@pone.0224858.ref019]\]                  Case-control study   USA                    Black and Caucasian                        58,4 ±\                  54,9            175 cases\                                    GWAS                          \                                      A GWAS study investigated the relationship between the SNPs and ACEi-AE; no genome-wide significant connection was found. However, there was moderate evidence that 16 SNPs from African-Americans and 41 SNPs from European-Americans wew associated with ACEi-AE (p \<10^−4^).\   55
                                                                                                                                             14,1                                     489 controls *(at least 6 months)*                                          *CPN*\                                 In a candidate gene analyses, there was a significant correlation between *MME* and ACEi-AE                                                                                                                                                                                         
                                                                                                                                                                                                                                                                  *MME*\                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                  *XPNPEP2*\                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                  *DPP4*\                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                  *BDKRB1*\                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                  *BDKRB2*\                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                  *TACR1*                                                                                                                                                                                                                                                                                                                    

  **Woodard-Grice 2010** \[[@pone.0224858.ref018]\]   Case-control study   USA                    Black and Caucasian                        57,3 ±\                  56,8            169 cases *(median of 5 months)*\             Allele-specific PCR           *XPNPEP2* C-2399A\                     The *XPNPEP2* C-2399A (*XPNPEP2* c.C-2400C\>A rs3788853)\                                                                                                                                                                                                                           45
                                                                                                                                             14,1                                     397 controls *(median of 42 months)*                                        (*XPNPEP2* c.C-2400C\>A rs3788853)     genotype was correlated with a greater risk of ACEi-AE in men                                                                                                                                                                                                                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACE: angiotension-converting enzyme; ACEi: ACE-inhibitor; ACEi-AE: ACE-inhibitor induced angioedema; ATRB-AE: Angiotensin II receptor blocker induced angioedema; *ACE* I/D: *ACE* insertion/deletion; APP: aminopeptidase P; ATRB: angiotensin receptor blocker; F: female; NS: not specified; OR: odds ratio; BDKRB2: bradykinin B2; BDKRB1: bradykinin B1; CPN: carboxypeptidase P; MME: neprilysin; XPNPEP2: aminopeptidase P; TACR1: NK1 receptor; GWAS: genome-wide association study; SD: standard deviation; Q-genie tool: quality of genetic association studies; RFLP: restriction fragment length polymorphism; PCR: polymerase chain reaction.

Study characteristics {#sec011}
---------------------

The included studies were published between 2005 and 2013. All seven studies had a case-control study design. The total number of included patients with ACE-AE was 547. Five studies described the ethnicity of patients. Three study populations were of mixed ethnicity; two of these studies included black and Caucasian patients, and the third study population consisted of blacks, Caucasian and Cape mixed-race patients. The remaining two studies had only included Caucasians patients\[[@pone.0224858.ref017],[@pone.0224858.ref022]\].

Three of the studies examined the relationship between the *ACE* I/D polymorphism and ACEi-AE, and none of them found any statistically significant associations \[[@pone.0224858.ref016],[@pone.0224858.ref017],[@pone.0224858.ref021]\]. In two of these studies, the relationship between the *Bradykinin B2 receptor* gene and ACEi-AE was also investigated, and four *Bradykinin receptor B2* gene polymorphisms were evaluated. There was reported a significant association between the *Bradykinin receptor B2--*9 /+ 9 and the risk of ACEi-AE \[[@pone.0224858.ref016],[@pone.0224858.ref021]\]. The other studied polymorphisms (*BDKRB2* C-58T, *BDKRB2* 2/3 *and BDKRB2* c.C181T) showed no significant associations with ACEi-AE.

Three of the studies suggested that ACEi-AE development was due to a lower concentration of APP. The *XPNPEP2* C-2399A genotype was associated with ACEi-AE \[[@pone.0224858.ref018]\]. In one of the studies, an ATG haplotype in the *XPNPEP2* 5\'-regulatory region was associated with a greater variance in plasma APP and thus increased the risk of developing ACEi-AE, due to a decreased degradation of BK \[[@pone.0224858.ref020]\].

A genome-wide association study (GWAS) was conducted in only one of the included studies \[[@pone.0224858.ref019]\]. No statistically significant correlation was found between any single nucleotide polymorphisms (SNP) and ACEi-AE after the Bonferroni correction for multiple testing was applied. However, moderate evidence for an association with ACEi-AE was reported (*p* \<10^−4^) for 16 SNP's in black patients and for 41 SNPs in Caucasian patients \[[@pone.0224858.ref019]\]. In this study, a candidate gene analysis was additionally performed to investigate polymorphisms in the following genes: *bradykinin B2*, *bradykinin B1*, *carboxypeptidase P*, *neprilysin*, *APP* and the *NK1 receptor*. One polymorphism in the *neprilysin* gene was associated with ACEi-AE \[[@pone.0224858.ref019]\].

Discussion {#sec012}
==========

This is the first systematic review to investigate the relationship between genetic markers and ACEi-AE using the Q-genie tool to evaluate the methodological approaches. The included studies examined different polymorphisms of *ACE* I/D polymorphism, *XPNPEP2* and the *Bradykinin B2 receptor* genes. In one of the studies, a GWAS and a subsequent candidate gene analysis were performed.

The *ACE* gene has a functionally relevant polymorphism. There is an alu repetition that is either present (I-allele) or absent (D-allele). It is suggested that the *ACE* D-allele is associated with higher serum enzyme activity than the I-allele \[[@pone.0224858.ref016]\]. This could mean that when the D allele is present, bradykinin is more readily degraded. The polymorphism of *ACE* I/D was not significantly associated with ACEi-AE. However all the three studies investigating this polymorphism were underpowered, and this could have affected the findings \[[@pone.0224858.ref016],[@pone.0224858.ref017],[@pone.0224858.ref021]\].

Since it has been shown that a low plasma activity of APP could be a predisposing factor for the development of angioedema during ACEi treatment \[[@pone.0224858.ref026]\], in three studies the polymorphism *XPNPEP2* of the *APP* gene was investigated, and a significant association with ACEi-AE was identified consistently in all three studies \[[@pone.0224858.ref018],[@pone.0224858.ref020],[@pone.0224858.ref022]\]. Those three studies included a total of 223 cases and 584 matched controls. However, there appeared to be some overlap between the study populations by Duan et al. and Cilia La Corte et al.\[[@pone.0224858.ref020],[@pone.0224858.ref022]\]. A functional haplotype was found in the 5'-regulatory region of *XPNPEP2*. This correlated with an increased risk of ACEi-AE due to decreased APP activity \[[@pone.0224858.ref020]\]. This haplotype could therefore be a marker for an increased risk of developing ACEi-AE, since decreased APP activity would potentially cause delayed BK degradation\[[@pone.0224858.ref020]\]

The GWAS investigated the relationship between the SNPs identified and ACEi-AE but no significant associations were found \[[@pone.0224858.ref019]\]. A total of 57 SNPs were identified, but there was only moderate evidence that any of these were associated with ACEi-AE. In addition, this moderate evidence was inconclusive because the associated *p*-values did not reach the level usually required in GWAS studies (*p* \< 10^−8^). The authors concluded that they were unable to establish any significant genome-wide association and suggested that the development of ACEi-AE may be influenced by multiple genetic factors. A candidate gene analysis was performed in spite of the non-significance of the GWAS findings, and a significant association was found between polymorphisms of the *neprilysin* gene and ACEi-AE \[[@pone.0224858.ref019]\].

In the study by Moholisa et al. they found a significant association between the genotype *B*~*2*~ + 9 / -9 and ACEi-AE, this significance was not found for the genotype *B*~*2*~*−*9 / -9. It should be noted that the control group was not in Hardy-Weinberg equilibrium, which affects the credibility of the association negatively \[[@pone.0224858.ref021]\]. Moreover, Bas et al. found no significant association between this polymorphism and ACEi-AE.

All of the included studies were evaluated using the Q-genie tool and achieved \"moderate \" or \"good\" quality scores. The scores are presented in [Table 1](#pone.0224858.t001){ref-type="table"} and [Fig 2](#pone.0224858.g002){ref-type="fig"}. [Table 1](#pone.0224858.t001){ref-type="table"} shows that the study by Pare et al. received the highest score (55 points) and was of good quality \[[@pone.0224858.ref019]\]. This study was carefully designed and described in detail. [Fig 2](#pone.0224858.g002){ref-type="fig"} shows this study's scores in each of the 11 aspects; its lowest score (3) was the \"*Non-technical classification of the exposure*\" (score 3).

![Scores for each study and the distribution of the 11 methodological aspects.](pone.0224858.g002){#pone.0224858.g002}

The study that scored the lowest was by Gülec et al., shown in [Table 1](#pone.0224858.t001){ref-type="table"} and [Fig 2](#pone.0224858.g002){ref-type="fig"} \[[@pone.0224858.ref017]\]. It received a score of 36 and was of moderate quality. This study was not particularly informative, and it failed to describe the procedures and how the results were achieved in sufficient detail.

[Fig 2](#pone.0224858.g002){ref-type="fig"} shows the overall scores for each study and the scores for each of the 11 questions obtained by each study. No study scored seven (excellent) for any of the questions. For question five: \"*Non-technical classification of the exposure*\" one study scored four and all the remaining studies scored less \[[@pone.0224858.ref017]\]. This indicates that the studies had not adequately reported how they performed the non-technical classification of the genetic variants, meaning that it is not clear whether it was a blinded assessor performed the genotyping. For question seven: \"*Sample size*\", two studies scored four the remaining studies scored less due to small sample sizes and the lack of a power calculation\[[@pone.0224858.ref018],[@pone.0224858.ref019]\]. Obtaining a sufficient sample size, and thus sufficient power, is difficult because ACE-AE is a rare adverse drug reaction. None of the studies performed a power calculation. In this regard, a collaboration between the different expert groups on ACEi-AE could minimize the issue of power by data sharing. One such group has already been formed in the PREDICTION-ADR consortium recruiting cases from five different countries, but further collaboration would be beneficial \[[@pone.0224858.ref027]\].

Question nine, \"*Statistical methods and control for confounding*\" evaluated the methods used to control for confounding variables, ensures that missing sample and genetic variant data have been correctly handled and checks that each study has tested for false positive results. Only one study scored five, and the remaining scored three or less \[[@pone.0224858.ref019]\]. The lower scores indicate that these concerns had not been adequately discussed. This is noteworthy because failing to consider the possible effect of confounding variables can lead to incorrect conclusions.

Many aspects need to be considered when designing a study, and it is important to describe procedures in detail to ensure the research can be replicated for further validation.

A recent case control study by Hubers et al. found that bradykinin level in acute ACEi-AE was elevated compared to treated controls, but there was no evidence of increased production through high-molecular-weight kininogen \[[@pone.0224858.ref028]\]. Also levels of the bradykinin degradation product bradykinin 1--5 (via ACE and neprilysin) was not increased even though the total levels were increased, which suggest impairment of non-ACE degradation pathways i.e. via neprilysin. This might suggest that polymorphisms in genes regulating these pathways would be associated with ACEi-AE; however Hubers et al. did not discuss the fact that increased levels of bradykinin can also arise due to increased production as is seen in some forms of hereditary angioedema \[[@pone.0224858.ref029]\].

Another issue regarding ACEi-AE is that some cases might suffer from rare types of angioedema i.e. hereditary angioedema associated with factor XII mutations \[[@pone.0224858.ref030],[@pone.0224858.ref031]\], which could be 'set off' by the ACE inhibition. In the future it would be desirable to genotype all ACEi-AE patients at least for the most common forms of hereditary angioedema.

Among the included studies, there were some differences in nomenclature used to describe polymorphisms. The Human Genome Variation Society (HGVS) nomenclature is recommended for clinical diagnostic reporting. This system includes a formats for describing variants with reference to sequence information, which can unambiguously specify positional information \[[@pone.0224858.ref032]\]. To avoid misunderstandings this nomenclature should be adhered to in future studies.

The Q-genie tool has some limitations. Using Q-genie to review a large number of studies is time consuming: it takes approximately 10 hours to review 30 studies, however it is estimated that Q-genie is more efficient than other tools, and reviewers will become more proficient at using Q-genie with practice \[[@pone.0224858.ref023]\]. Another limitation is that a study can have low scores for some of the 11 questions and still be "good" quality. In addition, despite the results, a good quality study can have a low score and therefore be considered low quality due to insufficient reporting of methods \[[@pone.0224858.ref033]\].

Conclusions {#sec013}
===========

This is the first systematic review that used the Q-genie tool to evaluate the quality of studies investigating ACEi-AE. Only one study was evaluated as "good quality". None of the studies performed a power calculation which is important for assessing the number of observations needed to detect a statistically significant association. The inferior quality of some studies was due to poor organization, lack of analyses and missing information. We recommended that these aspects are considered before undertaking future genetic studies because study reproducibility is very important. A collaboration between the different expert groups on ACEi-AE could minimize the issue of power by data sharing.

The polymorphisms in *XPEPNP2*, *BDKRB2*--9/+ 9 and *neprilysin* genes, were associated with an increased risk of developing ACEi-AE. However, due to low quality, these associations need to be confirmed in larger studies.

Supporting information {#sec014}
======================

###### Details on individual scores for the included studies based on Q-genie tool.

(DOCX)
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Click here for additional data file.
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Major Comments

1\) The results of this systematic review reveal only minor, if any, additional information.

2\) The manuscript appears to be poorly prepared. For instance, the in-text citation numbers do not match the citations of the bibliography. Examples are

line 76, citation 19,

page 7, the citation Duan 2005 in Table 1 and this citation is missing in the bibliography,

page 11, line 17, citation 15,

page 12, line 32, citation 21 is missing in the bibliography

page 13, line 56, citations 12 and 15

page 13, line 62, citation 22 is missing in the bibliography

Furthermore, some Results are presented twice as is the case for the overall quality scores which are given in Table 1 and additionally illustrated in Fig. 2. Likewise, S2 Table is superfluous as this information is included in S3 Table. The scientific message of Fig. 3 appears unclear to me as well.

The last chapter of the Abstract contains a duplication in line 36. Similarly, the same statement is given in line 123 and on page 11, line 12.

3\) The Discussion is for the most part a repetition of Results. I think it would have been important to discuss the at least the APP gene polymorphisms in more detail including the description and citation of the first report of reduced APP activity in patients with ACEi-angioedema (pubmed/12086766). On the other hand, the part of the discussion about the results of Hubers et al. is not correct as an increased concentration of bradykinin isn't necessarily caused by an impairment of bradykinin degradation (please refer to HAE). These authors based their conclusion on two further results, i.e. no change of the concentrations of the bradykinin degradation fragment B1-5 and the HMWK degradation product generated by kallikrein.

Reviewer \#2: This article represents the first systematic review on genetic markers in ACEi-AE and further discuss the methodology used. It properly addresses relevant points in the evaluation of the selected articles, the weakness of each studies and limitations imposed.

In the abstract, I expected to see a summary of the reliable genetic markers associated to ACEi-AE. But the only conclusion made was about the quality of the studies. I suggest including some relevant data regarding genetic susceptibility to ACEi-AE, as implied in the title and stated in the final conclusions.

Anecdotal evidences suggest that patients which present angioedema months after the withdrawn of ACEi cannot be classified as ACEi-AE but belong to another angioedema type. Although rare, a few reports support this hypothesis, describing FXII-HAE individuals that have been asymptomatic during their whole lives and only presented angioedema at advanced age when taking ACEis.

The use of Q-genie is interesting and strength the reliability of the selected articles. My only concern is that the focus of the article seems to be the methodology used and not the results of the analyzed studies. I expected a deeper discussion on the polymorphisms studied and the positive association found between them and ACEi-AE.

Although Moholisa\`s study find a significant association of +9/-9 genotype with both ACEi-cough and ACEi-AE, this association was not significant for the genotype -9/-9. Another point not highlighted is the fact that the control group was not in Hardy-Weinberg Equilibrium. The fact that Bas et al (2010) study did not found a significative association between this polymorphism and ACEi-AE also weakens its hypothetical influence in ACEi-AE. Another point to emphasize is the fact that --9/+9 was also nover significantly associated with worst prognosis in HAE, where bradykinin role is quite clear. Should you surely conclude the -9/+9 polymorphism to be associated to ACEi-AE?

I disagree that the word-count limit in scientific journal represents a limitation in properly reporting methods, as mentioned in lines 117-118. Currently, even articles published as short communications or brie reports have almost unlimited space in supplementary material.

As well pointed out by the authors, ACEi-AE in quite rare, hampering the power of all the analyzed studies. Besides the methodological recommendations for better organization to improve the quality of studies, the creation of consortium among expert groups on ACEi-AE could represent a big step into a larger and conclusive study on ACEi-AE susceptibility.

Minor

Line 43: Replace "ACEis inhibits the..." by ACEi inhibit the...".

Line 22: The reference 3, shown in the end of the sentence, should be withdrawn. Bas et al (2010) didn\`t found association between -9/+9 polymorphism and ACEi-AE.

In the Discussion (line 46), the authors say "The polymorphism of ACE I/D were significantly associated with AEi-AE. I think you wanted to say, "were not significantly associated", right?

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

16 Oct 2019

To the esteemed editor and reviewers

The authors thank you for your decision letter from PLOS ONE. We greatly appreciate the constructive comments. We have now addressed these comments, and believe this has strengthened the paper. On the following pages, we outline point-by-point responses to the comments by the reviewers. We look forward to hearing from you in the near future.

• We note that the original search was performed from January 2018 to August 2018. Please discuss whether relevant literature has been published in the interim that would be expected to affect the results of the meta-analysis. Additionally, please include the description of their search strategy and search terms in the methods section of the manuscript.

Response: A follow-up literature search was performed September 2019 and no further relevant papers were published since the original search. A description of our search strategy is now included in the methods section. Table S1 has been removed since the content is now included in the manuscript.

Reviewer\'s Responses to Questions

• Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

Response: The authors thank the reviewers.

• Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

Reviewer \#2: Yes

Response: The authors thank the reviewers for this notion.

• Have the authors made all data underlying the findings in their manuscript fully available? We requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

Response: The authors have made all data available in the tables, figures and supplementary material. There are no more data than that. We will be glad to share anything, so please specify any lacking information.

• Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

Response: The manuscript has undergone professional English language revision by Dr. Bobby Brown, Medical Writing Services Member of the European Medical Writers Association, UK. If of any interest, we can send the esteemed editor and reviewers the invoice as proof hereof.

Review Comments to the Author

• Reviewer \#1: Ali et al. performed a systematic review to evaluate the current evidence of an association of genetic polymorphisms with ACEi-angioedema. Among the seven studies included, significant associations were reported in four studies regarding XPEPNP2, BDKRB2 -9/+ 9 and Neprilysin gene polymorphisms. Of note, only the significant association with XPEPNP2 polymorphisms was consistently reported in three different studies. The authors conclude that the significant associations of genetic polymorphisms with ACEi-angioedema exist despite the limited quality of the studies estimated with the Q-genie tool.

Major Comments

1\) The results of this systematic review reveal only minor, if any, additional information.

Response: The authors agree, we have now adapted the manuscript accordingly. The conclusion has been re-written as we cannot assess whether there is actually a significant association due to the low quality of the studies.

• 2) The manuscript appears to be poorly prepared. For instance, the in-text citation numbers do not match the citations of the bibliography. Examples are

line 76, citation 19,

page 7, the citation Duan 2005 in Table 1 and this citation is missing in the bibliography,

page 11, line 17, citation 15,

page 12, line 32, citation 21 is missing in the bibliography

page 13, line 56, citations 12 and 15

page 13, line 62, citation 22 is missing in the bibliography

Response: Thanks to the reviewer for mentioning this mismatch between the text and bibliography. This was due to an error in our reference-managing program which happened probably shortly before the submission. The authors have been through the citations and adapted the manuscript.

• Furthermore, some Results are presented twice as is the case for the overall quality scores which are given in Table 1 and additionally illustrated in Fig. 2. Likewise, S2 Table is superfluous as this information is included in S3 Table. The scientific message of Fig. 3 appears unclear to me as well.

Response: In accordance to the reviewer's comment, we have now adapted the manuscript. There is a consensus that Fig. 2 and S2 Table are removed. However, we believe that Fig. 3 (now figure 2 in the manuscript) illustrates nicely, where the problem lies precisely with the quality of each study. In addition, the authors believe that for full data-sharing this figure is nice to be kept.

• The last chapter of the Abstract contains a duplication in line 36. Similarly, the same statement is given in line 123 and on page 11, line 12.

Response: The authors thank the reviewer for this comment; we have now adapted the manuscript accordingly to remove the repetitions.

• The Discussion is for the most part a repetition of Results. I think it would have been important to discuss the at least the APP gene polymorphisms in more detail including the description and citation of the first report of reduced APP activity in patients with ACEi-angioedema (pubmed/12086766).

Response: The authors thank the reviewer for this constructive comment; we have now revised the whole discussion section accordingly. A section on APP gene has been added to the discussion, including the study by Adam et al, Lancet, 2002. We believe this has improved the manuscript.

• On the other hand, the part of the discussion about the results of Hubers et al. is not correct as an increased concentration of bradykinin isn't necessarily caused by an impairment of bradykinin degradation (please refer to HAE). These authors based their conclusion on two further results, i.e. no change of the concentrations of the bradykinin degradation fragment B1-5 and the HMWK degradation product generated by kallikrein.

Response: The author agree that there is no definite conclusion that the increased level of bradykinin is due to the decreased degradation rates and it may also be caused by increased production rate. The manuscript has been amended accordingly.

• Reviewer \#2: This article represents the first systematic review on genetic markers in ACEi-AE and further discuss the methodology used. It properly addresses relevant points in the evaluation of the selected articles, the weakness of each studies and limitations imposed.

In the abstract, I expected to see a summary of the reliable genetic markers associated to ACEi-AE. But the only conclusion made was about the quality of the studies. I suggest including some relevant data regarding genetic susceptibility to ACEi-AE, as implied in the title and stated in the final conclusions.

Response: The authors agree with this comment and changes have been made to the abstract. However no firm conclusions can be drawn, so how reliable the markers are is also discussed.

• Anecdotal evidences suggest that patients which present angioedema months after the withdrawn of ACEi cannot be classified as ACEi-AE but belong to another angioedema type. Although rare, a few reports support this hypothesis, describing FXII-HAE individuals that have been asymptomatic during their whole lives and only presented angioedema at advanced age when taking ACEis.

Response: This has been included in the discussion and is a very valid point. This interesting case has been included as reference: Veronez CL, Serpa FS, Pesquero JB. A rare mutation in the F12 gene in a patient with ACE inhibitor-induced angioedema. Ann Allergy Asthma Immunol 2017; 118(6): 743-5.

• The use of Q-genie is interesting and strength the reliability of the selected articles. My only concern is that the focus of the article seems to be the methodology used and not the results of the analyzed studies. I expected a deeper discussion on the polymorphisms studied and the positive association found between them and ACEi-AE.

Response: The authors agree and have now added a new part to the discussion where the polymorphisms are discussed and their positive association found between them and ACEi-AE.

• Although Moholisa\`s study find a significant association of +9/-9 genotype with both ACEi-cough and ACEi-AE, this association was not significant for the genotype -9/-9. Another point not highlighted is the fact that the control group was not in Hardy-Weinberg Equilibrium. The fact that Bas et al (2010) study did not found a significative association between this polymorphism and ACEi-AE also weakens its hypothetical influence in ACEi-AE. Another point to emphasize is the fact that --9/+9 was also never significantly associated with worst prognosis in HAE, where bradykinin role is quite clear. Should you surely conclude the -9/+9 polymorphism to be associated to ACEi-AE?

Response: The authors agree and a section on this has been added in the discussion.

• I disagree that the word-count limit in scientific journal represents a limitation in properly reporting methods, as mentioned in lines 117-118. Currently, even articles published as short communications or brie reports have almost unlimited space in supplementary material.

Response: The authors agree, we have now adapted the manuscript accordingly.

• As well pointed out by the authors, ACEi-AE in quite rare, hampering the power of all the analyzed studies. Besides the methodological recommendations for better organization to improve the quality of studies, the creation of consortium among expert groups on ACEi-AE could represent a big step into a larger and conclusive study on ACEi-AE susceptibility.

Response: This is very true, thanks for pointing this out, it has been implemented. Some of the authors are already involved in the PREDICTION-ADR consortium and genetic samples from our original study (unpublished data) have been shipped to Germany for inclusion in another larger study of ACEi-AE genetic markers. So things are improving, we believe.

• Minor

Line 43: Replace "ACEis inhibits the..." by ACEi inhibit the...".

Line 22: The reference 3, shown in the end of the sentence, should be withdrawn. Bas et al (2010) didn\`t found association between -9/+9 polymorphism and ACEi-AE.

In the Discussion (line 46), the authors say "The polymorphism of ACE I/D were significantly associated with AEi-AE. I think you wanted to say, "were not significantly associated", right?

Response: Yes, we have now inserted a "not" in the sentence.
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Dear Dr. Rasmussen,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Michael Bader

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

Reviewer \#2: N/A

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: I have no further comments, although I still think that is does provide only minor additional information.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No
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Genetic susceptibility to angiotensin-converting enzyme-inhibitor induced angioedema: a systematic review and evaluation of methodological approaches

Dear Dr. Rasmussen:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Michael Bader

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
